Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
|Slideshows|October 2, 2017
3 Novel Technologies for Geriatric Psychiatry
Author(s)Mark L. Fuerst
New tools for the armamentarium: a patient self-management app, a retinal imaging system, and a computer program for Alzheimer diagnosis.
Advertisement
View the slides in PDF format.
Advertisement
Related to this article
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
4
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
5